Chemical Structure : WMJ-J-09
Catalog No.: PC-24736Not For Human Use, Lab Use Only.
WMJ-J-09 a potent, hydroxamate based HDAC inhibitor, exhibits potent inhibitory activity against class I HDACs, including HDAC1 (IC50=7.5 nM), HDAC2 (IC50=21.3 nM), HDAC3 (IC50=18.4 nM), and HDAC8 (IC50=90.9 nM), also strongly inhibitsHDAC6 (class IIb) with IC50 of 3.9 nM.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
WMJ-J-09 a potent, hydroxamate based HDAC inhibitor, exhibits potent inhibitory activity against class I HDACs, including HDAC1 (IC50=7.5 nM), HDAC2 (IC50=21.3 nM), HDAC3 (IC50=18.4 nM), and HDAC8 (IC50=90.9 nM), also strongly inhibitsHDAC6 (class IIb) with IC50 of 3.9 nM.
WMJ-J-09 arrests the cell cycle and induced apoptosis in HCT116 cells.
WMJ-J-09 shows moderate inhibition toward HDAC4 (class IIa) with an IC50 of 8715.7 nM.
WMJ-J-09 significantly reduces the polymerized tubulin fraction through HDAC inhibition.
WMJ-J-09 caused HCT116 cell death may involve p21 elevation and survivin suppression.
WMJ-J-09 triggers LKB1-p38MAPK-p53 signaling pathway to increases p21 expression and survivin reduction, culminating in HCT116 cell death.
WMJ-J-09 induced survivin degradation.
WMJ-J-09 (20 mg/kg/day) inhibits growth of the HCT116 tumor xenograft, does not impact mouse body weight.
M.Wt | 445.53 | |
Formula | C22H27N3O5S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
1. Yen CS, et al. Front Pharmacol. 2018 Mar 1;9:167.
2. Huang YH, et al. Sci Rep. 2025 Jun 4;15(1):19590.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright